TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology
The robust, high-quality data and clinical studies supporting the use of Abiomed's (NASDAQ:ABMD) Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure patients will be showcased at Transcatheter Cardiovascular Therapeutics (TCT) 2021, the annual scientific symposium of the Cardiovascular Research Foundation. The conference will meet virtually and in-person in Orlando, Florida, on November 4 – 6.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211101005297/en/
Impella CP with SmartAssist, shown placed in the heart’s left ventricle. (Photo: Business Wire)
Impella heart pumps are the world’s smallest heart pumps. They unload the heart while providing coronary and end organ perfusion. Impella SmartAssist technology enables improved patient outcomes via real-time intelligence. Abiomed augments limited hospital resources by providing 24x7 support on-site, on-call and online.
Throughout TCT, and at a pre-conference workshop on November 3, leading physician-researchers will present data demonstrating:
- Complete revascularization with Impella improves ejection fraction and long-term patient outcomes.
- Cardiogenic shock best practices, including early unloading with Impella pre-PCI and timely escalation to Impella RP and Impella 5.5 with SmartAssist, are associated with improved survival and native heart recovery.
During TCT 2021, physicians will detail final results from two large studies of Impella -- the PROTECT III post approval study and the RESTORE EF study. Interim results from both studies were presented at TCT 2020 and demonstrated the benefits of using contemporary practices to achieve complete revascularization with Impella.
The high-quality clinical evidence being generated from the PROTECT series of studies includes the PROTECT II randomized controlled trial (RCT) and the ongoing PROTECT IV RCT of Impella use in high-risk PCI patients. Based on PROTECT II RCT data, and data from additional robust prospective clinical studies, the United States Food and Drug Administration (FDA) granted Impella premarket approvals (PMA) as safe and effective for high-risk PCI, cardiogenic shock and right heart failure.
TCT presenters will also review the real-world evidence (RWE) and best practices gathered since Impella’s FDA approvals. This evidence will inform the RECOVER IV RCT of Impella use in cardiogenic shock patients. The RWE includes prospective data from the National Cardiogenic Shock Initiative (NCSI) Study, J-PVAD Study and INOVA Study. These datasets demonstrate cardiogenic shock best practices, including early use of Impella, are associated with improved survival rates of 71%, 77% and 82% (respectively), compared to the historical cardiogenic shock survival rate of about 50%.
In-person attendees of TCT 2021 are invited to visit Abiomed at the TCT Industry Hub, which will be open from 8:00 am – 5:30 pm EDT. At the Hub, attendees will be able to participate in hands-on Impella demonstrations, view the newest technologies, talk with members of the Abiomed product development team, and learn the latest information about Abiomed’s ongoing and planned randomized controlled trials.
Virtual attendees of TCT 2021 are invited to participate in three ways:
- Visit www.HeartRecovery.com 24x7 to experience Abiomed’s virtual cath lab and view live and on-demand TCT-related video content.
- Follow the @HeartRecovery and @ProtectedPCI Twitter handles for the latest TCT news and events.
- Tune in for the live TCT recap program, livestreamed on www.HeartRecovery.com at 6:00 pm EDT on Thursday, November 4, and Friday, November 5. Chuck Simonton, MD, and Seth Bilazarian, MD, from the Abiomed medical office will present the top TCT news of the day. After the live broadcast, the program will be available for on-demand viewing.
In-person and virtual participants of TCT are invited to attend a breakfast symposium on Thursday, November 4. The principal investigators of the PROTECT IV RCT, the RECOVER IV RCT and the STEMI Door-to-Unloading RCT will update the physician community on the progress of those trials. The symposium will also review the clinical experience with the new 9 French Impella ECP heart pump. The schedule of presentations and instructions for in-person and virtual viewing are below:
Clinical Science to Landmark Trials of Left Ventricular Unloading in High-Risk PCI and Cardiogenic Shock
Date: Thursday, November 4, 2021
Time: 6:30 – 7:30 am EDT
In-Person Location: Orange County Convention Center, Clinical Science Theater, Level 1, Halls A & B
Virtual Location: Watch via the official TCT 2021 conference livestream
Presenters:
- PROTECT Series Leading to PROTECT IV, Gregg Stone, MD, Mount Sinai Health System, New York City
- Real World Evidence Leading to RECOVER IV, William O’Neill, MD, Henry Ford Hospital, Detroit
- Door to Unload: Implications for STEMI, High-Risk PCI and Cardiogenic Shock, Navin Kapur, MD, Tufts Medical Center, Boston
- Breaking the Small-Bore Barrier: Impella ECP 9 Fr Heart Pump Clinical Experience, Amir Kaki, MD, Ascension St. John Hospital, Detroit
In conjunction with TCT, Abiomed is also hosting a pre-meeting workshop on November 3 for members of CAMP PCI. CAMP PCI (Coronary Artery & Myocardial Protected PCI) is the leading online and in-person physician education platform dedicated to improving patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques and technologies to enable safer, more effective and complete revascularization.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® devices are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
The Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005297/en/
Contact information
Media Contact:
Tom Langford
Director of Communications
+1 (978) 882-8408
tlangford@abiomed.com
Investor Contact:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech and Equinor Expand Digital Collaboration2.7.2025 14:08:00 EEST | Press release
HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e
Wizz Air Tops Major Airline Emissions Rankings2.7.2025 12:00:00 EEST | Press release
Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/ The top 20 Major airlines globally, ranked by lowest CO2/ASK Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report. The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments. The rankings performance use Cirium's EmeraldSky platform, which achieved ISAE 3000 Reasonable Assurance from PricewaterhouseCoopers (PwC) and official accreditation from the Roc
L&T Technology Services Chosen by TRATON GROUP as Strategic Engineering Partner in Global R&D Transformation2.7.2025 11:59:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), today announced that it has been chosen by the TRATON GROUP, one of the world’s leading manufacturers of commercial vehicles, as a strategic engineering partner. This collaboration in LTTS’ Mobility segment will support TRATON’s roadmap to build a unified, future-ready product-development platform that delivers scale, speed, and sustainable mobility solutions worldwide. TRATON is reshaping its global R&D ecosystem to unlock cross-brand synergies while expanding the share of battery-electric vehicles in line with its 2029 profitability and sustainability targets. LTTS’ selection will see the company provide engineering support, from mechanical and software engineering to digital systems integration - across key development hubs in Sweden, Germany, the United States, Poland, and India. The collaboration positions LTTS to deepen existing workstreams and pursue new programs across TRATON’s brands, spanning software-defined vehicle architect
Nexo Becomes First-Ever Digital Wealth Platform of the DP World Tour, Launches Nexo Championship2.7.2025 11:30:00 EEST | Press release
Nexo, the premier digital assets wealth platform, has signed a three-year landmark partnership with the DP World Tour, becoming an Official Marketing Partner and the Tour’s Official Digital Wealth Platform through 2027. This agreement marks the first-ever multi-year partnership between a digital assets company and a major global golf tour — a historic convergence of crypto and golf — reflecting both organizations’ shared commitment to performance, innovation, and a global outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702770847/en/ Nexo becomes the first-ever Official Digital Wealth Platform of the DP World Tour. Nexo has also become the Title Partner of the newly renamed Nexo Championship — previously the Scottish Championship — taking place from August 7–10, 2025. The tournament is set at the Trump International Golf Links in Aberdeenshire, which has earned a reputation as one of the finest modern links courses
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta2.7.2025 11:00:00 EEST | Press release
Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications.1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI.3 The trial compared the efficacy and safety of follitropin delta and follitropin alfa using conventional dosing regimens with a primary endpoint of number of oocytes retrie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom